Skip to main content
Back to grants dashboard
ClosedUpdated 9 Jun 2026Mixed

Contracts for Innovation: industrial human relevant drug models

Innovate UK · United Kingdom

This competition supports organisations to develop innovative, human-relevant drug testing models to improve the efficiency, accuracy, and ethical standards of drug discovery and development.

Summary

Deadline

1 May 2026

Complexity

Medium

Time to apply

20-60 hours

Updated

9 Jun 2026

This competition supports organisations to develop innovative, human-relevant drug testing models to improve the efficiency, accuracy, and ethical standards of drug discovery and development.

Eligibility

Applicant types

Business, Research, Public Sector

Business size

SME, Large

Industries

Life sciences, pharmaceuticals, biotechnology, biomedical research

Match funding

Needs verification

Requirements

UK-registered organisations including businesses, research organisations, and public sector bodies Single legal entity; UK or international organisation may lead per CfI competition terms. Development of human-relevant drug testing models, including alternatives to animal testing and advanced in vitro or in silico systems

Eligible applicants

UK-registered organisations including businesses, research organisations, and public sector bodies

Funding and scope

Benefit amount

£2,000,000

Total fund available

£2,000,000

Funding intensity

Not specified

Payment type

Reimbursement (in arrears)

Eligible scope

Development of human-relevant drug testing models, including alternatives to animal testing and advanced in vitro or in silico systems

Eligible expenses

  • Project delivery costs including staff, materials, and operational costs required for developing proposed solutions

Ineligible costs

  • Costs outside CfI industrial human relevant drug models scope.

Application and risks

Application platform

Innovation Funding Service (IFS)

Competitiveness

Closed / Not accepting applications

Decision timeline

Not specified

Assessment process

Applications assessed by independent experts with funding awarded based on scoring and available budget

Application sections

Not specified

Application components

  • Online application including project proposal, costs, and organisational details

Required documents

Not specified

Appendices

Not specified

Assessment criteria

  • Innovation potential, feasibility, value for money, and alignment with competition objectives

Timeline and partners

Opening date

2 Mar 2026

Project duration

Not specified

Project start

Not specified

Project end

Not specified

Co-funders

Not specified

Collaboration rules

  • Not explicitly specified

Consortium requirements

  • Contracts awarded to single legal entity; subcontractors as permitted in IFS guidance.

Additional guidance

[{"label":"Key Organisational Requirements","value":"Applicants must be UK-registered and capable of delivering innovation projects aligned with competition scope"},{"label":"Funding Structure","value":"100% funded contracts for innovation projects (no match funding required)"},{"label":"important notes","value":"Delivered as a procurement-style contract; projects are fully funded; strong focus on ethical and scientific advancement in drug testing"}]

Quick facts

Status
Closed
Deadline
1 May 2026
Funding amount
£2,000,000
Funding band
Small (£50k-£500k)
Funding type
Grant
Payment type
Reimbursement (in arrears)
Audience
Business, Research Innovation, Public Sector, Mixed
Industry
Life sciences, pharmaceuticals, biotechnology, biomedical research
Last updated
9 Jun 2026
Published
2 Mar 2026